Precision: Lung Cancerwill bring together scientists and business leaders from pharma, biotech and academia, using extensive networking sessions to forge meaningful collaborations. Discussions will revolve around translating the latest developments in the genomic and molecular understanding of the disease into new targeted therapies in the clinic.
